Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Mirum Pharmaceuticals International B.V., Kingsfordweg 151, 1043 GR Amsterdam, Netherlands
Livmarli 9.5 mg/mL oral solution.
Pharmaceutical Form |
---|
Oral solution. Clear, colourless to light-yellow liquid. |
Each mL of solution contains maralixibat chloride equivalent to 9.5 mg maralixibat.
Excipient with known effect: Each mL of oral solution contains 364.5 mg propylene glycol (E1520).
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Maralixibat |
Maralixibat is a minimally absorbed, reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Maralixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. |
List of Excipients |
---|
Propylene glycol (E1520) |
30 mL amber-coloured PET bottle with a preinstalled LDPE adapter and a HDPE child-resistant closure with a foam liner, containing 30 mL oral solution.
Pack size:
Each pack contains one 30 mL bottle and is co-packaged with three oral repeated-use syringes (0.5 mL, 1 mL and 3 mL) with the following graduations:
Mirum Pharmaceuticals International B.V., Kingsfordweg 151, 1043 GR Amsterdam, Netherlands
EU/1/22/1704/001
Drug | Countries | |
---|---|---|
LIVMARLI | Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, Romania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.